Alnylam launches symptom tracker app for rare disease
Alnylam Pharmaceuticals has launched a digital symptom tracker to support people in the UK with the rare disease ATTR amyloidosis.
The STAR app allows patients to record their symptoms and share information with their doctor during or in between consultations.
Professor Philip Hawkins, professor of medicine, National Amyloidosis Centre, UK, said: “ATTR amyloidosis is a rapidly progressive multisystem disease that is characterized by increasing complexity and severity of symptoms. Because the disease can evolve over time, it is important for patients to accurately track any changes in their symptoms.”
UK startup FIKA raises £1.2m for workplace mental fitness training platform
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
London-based startup FIKA has raised £1.2 million in seed funding from lead investor Rising Stars and a syndicate of 10 expert angel investors.
FIKA’s mental health fitness platform provides employees with a series of short, personalized courses, developed in partnership with performance psychologists.
The funding will go towards expanding the team across all business functions, driving its first go-to-market strategy, and supporting further R&D, particularly the development of its mental fitness technology, diagnostic tools, and AI-driven personalized pathways.
Source: Mobihealthnews
